Dosing for IgG and especially IgG2 anti-TIF1γ in adult dermatomyositis would refine cancer risk assessment

Anti-transcription intermediary factor 1 γ (TIF1γ) autoantibodies are associated, in adults with dermatomyositis, with an excess risk of cancer.

A French study involving clinicians from the Institute of Myology had shown in 2019 that anti-TIF1γ of IgG2 subtype could be a biomarker of this tumor risk. A result confirmed by a retrospective international study conducted under the aegis of the European NeuroMuscular Center in 132 adults with dermatomyositis with anti-TIF1γ:

• 54.5% had an associated cancer;
• their anti-TIF1γ IgG2 levels were higher than those of participants who did not develop cancer, on average 1.1 versus 0.50 AU/ml ;
• anti-TIF1γ IgG levels were also higher with associated cancer than without, 127.5 vs 93 AU/ml.

 

The IgG2 Isotype of Anti-Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis. Aussy A, Fréret M, Gallay L et al. Arthritis Rheumatol. 2019 Aug;71(8):1360-1370.

 

Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study. Cordel N, Dechelotte B, Jouen F et al. Rheumatology (Oxford). 2022 Oct 17:keac577.